The 2006 ILLUMINATE clinical trial used Torcetrapib, a novel selective cholesteryl ester transfer protein (CETP) inhibitor, to improve HDL plasma levels in patients with ASCVD, and showed that the all-cause mortality increased with elevated HDL levels [106]. The gene discussed is CETP; the disease is atherosclerosis.